Stocks Roundup: ArcelorMittal (NYSE:MT), Horizon Pharma plc (NASDAQ:HZNP)

79

ArcelorMittal (NYSE:MT)

The company announced its last quarter financial performance results on 11/04/2016. ArcelorMittal (NYSE:MT) belongs to Basic Materials sector that declined -3.04% in value when last trading session closed at $7.66. The company has a market capitalization of $25.47 Billion. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of -11.2 percent. The company reached its 52-Week high of $8.84 on Dec 8, 2016 and 52-Week low of $2.93 on Feb 11, 2016.

Earnings per share (ttm) for ArcelorMittal (NYSE:MT) according to Finviz Data is $-1.88.

This company was Upgrade by RBC Capital Mkts on 25-Nov-16  to Outperform.

The 31 analysts offering 12-month price forecasts for ArcelorMittal have a median target of 7.62, with a high estimate of 12.00 and a low estimate of 3.72. The median estimate represents a -0.56% decrease from the last price of 7.66.

Financial History:

Following Earnings result, share price were DOWN 5 times out of last 7 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  0 times and missed earnings  3  times.

The consensus recommendation for ArcelorMittal (NYSE:MT) is 2. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2. In comparison, the consensus recommendation 60 days ago was at 1.67, and 90 days ago was at 1.67 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects ArcelorMittal to have earnings per share of $0.07.

Revenue is expected to range from 14.03 Billion to 14.03 Billion with an average of 14.03 Billion.

Company Profile:

ArcelorMittal (MT) is the world’s leading steel and mining company. With a presence in more than 60 countries, it operates a balanced portfolio of cost competitive steel plants across both the developed and developing world. It is the leader in all the main sectors automotive, household appliances, packaging and construction. The company is also the world’s fourth largest producer of iron ore, with a global portfolio of 16 operating units with mines in operation or development.

Horizon Pharma plc (NASDAQ:HZNP):

Horizon Pharma plc (NASDAQ:HZNP) belongs to Medical sector closed its last session with a gain of 10.11 percent and closed its previous trading session at $16.44. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.08. The company has the Market capitalization of $2.69 Billion. The company’s stock has a Return on Assets (ROA) of -0.4 percent, a Return on Equity (ROE) of -0.9 percent and Return on Investment (ROI) of 3 percent. The company reached its 52-Week high of $23.44 on Aug 15, 2016 and 52-Week low of $13.05 on May 6, 2016.

This company was Upgrade by Mizuho on 16-Dec-16 to Buy.

The 12 analysts offering 12-month price forecasts for Horizon Pharma PLC have a median target of 25.50, with a high estimate of 42.00 and a low estimate of 14.00. The median estimate represents a +55.11% increase from the last price of 16.44.

Financial History:

Following Earnings result, share price were UP 11 times out of last 21 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  1 times and missed earnings  7  times.

The consensus recommendation for Horizon Pharma plc (NASDAQ:HZNP) is 1.29. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.29. In comparison, the consensus recommendation 60 days ago was at 1.57, and 90 days ago was at 1.57 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Horizon Pharma plc to have earnings per share of $0.53.

Revenue is expected to range from 271.6 Million to 314 Million with an average of 306.95 Million.

Company Profile:

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.